 December 13, 2006
| Topic: |
Jesse revisited:
What really happened and what have we learned? |
| Presenter: |
Barbara G. Bigby, Director, Scripps Office for the Protection of Research Subjects |
| Location: |
SDSU Foundation: Sky Park |
| Discussion: |
Seven years after Jesse’s Gelsinger’s untimely death in a gene therapy protocol at the University of Pennsylvania, little new information has circulated about the causes underlying his reaction to the study drug. Most research in this area has been conducted by scientists in Wilson’s own lab. References to Jesse continue to cite allegations that were circulated in 1999; little attempt has been made to re-examine the events and attempt to obtain a current perspective. Ms. Bigby's interest in this was precipitated by a student in her Human Subjects Protections and IRBs class who was a former fellow in the Wilson lab. He was by no means an apologist for Wilson, but he was concerned that propagation of half-truths did not further the cause of research ethics training. |
| Readings: |
- Sherman, Silverstein, Kohl, Rose & Podolsky website, court documents: http://www.sskrplaw.com/links/healthcare2.html
- "Preliminary Findings Reported on the Death of Jesse Gelsinger." The Institute for Human Gene Therapy, University of Pennsylvania (PDF 2 pages)
- Raper, Steven E., et al. "Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer." Molecular Genetics and Metabolism, Volume 80, Issues 1-2, September-October 2003, Pages 148-158, Science Direct, (online PDF, 11 pages)
- "Jesse's Intent." All rights reserved Paul Gelsinger. Presented by Paul Gelsinger: IRBs: New Directions in 2000, October 31, 2000, San Diego, CA. (PDF 8 pages)
|
|
